# A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

> **NCT06609226** · PHASE3 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 480 (estimated)

## Conditions studied

- Sickle Cell Disease
- Thalassemia

## Interventions

- **DRUG:** Etavopivat A
- **DRUG:** Etavopivat B
- **DRUG:** Etavopivat C

## Key facts

- **NCT ID:** NCT06609226
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2030-12-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06609226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06609226, "A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06609226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*